Immunome (IMNM) to Release Earnings on Thursday

Immunome (NASDAQ:IMNM) is projected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $3.16 million for the quarter.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Price Performance

IMNM stock opened at $6.95 on Wednesday. The company has a market capitalization of $604.31 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. Immunome has a 1-year low of $6.94 and a 1-year high of $26.70. The business has a 50 day simple moving average of $9.67 and a two-hundred day simple moving average of $11.44.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IMNM. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Guggenheim cut their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens restated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $25.50.

Insider Buying and Selling

In related news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CTO Philip Tsai acquired 12,300 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were bought at an average price of $8.42 per share, with a total value of $103,566.00. Following the acquisition, the chief technology officer now directly owns 33,300 shares in the company, valued at $280,386. This represents a 58.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 169,300 shares of company stock valued at $1,323,536. Insiders own 8.60% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.